MIRA Pharmaceuticals (NASDAQ:MIRA) Earns Buy Rating from Analysts at Maxim Group

Posted by on Sep 17th, 2026

Investment analysts at Maxim Group started coverage on shares of MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) in a report issued on Thursday, Benzinga reports. The firm set a “buy” rating and a $3.50 price target on the stock. Maxim Group’s price target suggests a potential upside of 376.19% from the company’s current price.

Separately, Weiss Ratings cut MIRA Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 20th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $3.50.

Get Our Latest Research Report on MIRA Pharmaceuticals

MIRA Pharmaceuticals Stock Performance

MIRA traded up $0.02 during trading on Thursday, reaching $0.73. The stock had a trading volume of 39,059 shares, compared to its average volume of 294,552. The business has a 50-day moving average of $0.80 and a 200-day moving average of $0.96. MIRA Pharmaceuticals has a one year low of $0.60 and a one year high of $2.45. The stock has a market cap of $30.88 million, a PE ratio of -0.59 and a beta of 1.52.

MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.03) EPS for the quarter.

Institutional Trading of MIRA Pharmaceuticals

A hedge fund recently bought a new position in MIRA Pharmaceuticals stock. BlackRock Inc. acquired a new stake in shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA – Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 244,622 shares of the company’s stock, valued at approximately $232,000. BlackRock Inc. owned approximately 0.58% of MIRA Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 35.16% of the company’s stock.

MIRA Pharmaceuticals Company Profile

(Get Free Report)

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.

Read More

Receive News & Ratings for MIRA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MIRA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.